Strategies for Increasing Drug Delivery to the Brain
Reference94 articles.
1. Abrey, L.E., Yahalom, J. and DeAngelis, L.M. (2000). Treatment for primary CNS lymphoma: the next step. J Clin Oncol, 18, 3144–3150. 2. Aubree-Lecat, A., Duban, M.C., Demignot, S., Domurado, M., Fournie, P. and Domurado, D. (1993). Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target. J Pharmacokinet Biopharm, 21, 75–98. 3. Balis, F.M., Blaney, S.M., McCully, C.L., Bacher, J.D., Murphy, R.F. and Poplack, D.G. (2000). Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol, 45, 259–264. 4. Balis, F.M., Savitch, J.L., Bleyer, W.A., Reaman, G.H. and Poplack, D.G. (1985). Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol, 3, 485–489. 5. Balmaceda, C., Gaynor, J.J., Sun, M., Gluck, J.T. and DeAngelis, L.M. (1995). Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol, 38, 202–209.
|
|